This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Care

ASCO '15: J&J Antibody Benefits Patients With Hardest-to-Treat Multiple Myeloma

ASCO '15: J&J Antibody Benefits Patients With Hardest-to-Treat Multiple Myeloma

  • Tickers in this article:
  • JNJ

J&J intends to seek approval for daratumumab later this year.

05/30/15 - 07:35 AM EDT

ASCO '15: CTI Biopharma Takes on Myelofibrosis Drug Rival

The CTI Bio drug pacritinib is mostly effective for a small percentage of myelofibrosis patients with dangerously low platelet counts, according to new data from a phase III study.

05/30/15 - 07:30 AM EDT

Try Jim Cramer's Action Alerts PLUS
Humana Shares Spike on Rumors of Takeover Humana Shares Spike on Rumors of Takeover

Humana Shares Spike on Rumors of Takeover

Humana ended Friday's trading session up 20%, making it TheStreet's Move of the Day.

05/29/15 - 05:19 PM EDT

Stocks Post May Gain; Humana Considers Sale

Stocks Post May Gain; Humana Considers Sale

A sad day for American Express (AXP) as President Ed Gilligan passed away after 35 years at the company.

05/29/15 - 04:50 PM EDT

Humana Shares Spike 20 Percent After Takeover Report Surfaces

Humana Shares Spike 20 Percent After Takeover Report Surfaces

Shares of Humana (HUM) ended Friday's trading session up 20 percent, making it TheStreet's Move of the Day.

05/29/15 - 04:46 PM EDT

ASCO '15: Merck, Bristol Drugs Boost Immune System to Kill Broad Swath of Cancer Types

ASCO '15: Merck, Bristol Drugs Boost Immune System to Kill Broad Swath of Cancer Types

  • Tickers in this article:
  • BMY
  • MRK

The class of cancer immunotherapy drugs which target the protein PD-1 is proving to be effective against advanced liver, head and neck, lung and colon cancers.

05/29/15 - 02:00 PM EDT

Jim Cramer's Stop Trading: Lilly's AstraZeneca Partnership Is a ‘Brilliant’ Move

Jim Cramer's Stop Trading: Lilly's AstraZeneca Partnership Is a ‘Brilliant’ Move

  • Tickers in this article:
  • LLY
  • AZN

Lilly 'never stops innovating,' Jim Cramer said of the plan to test a new cancer drug combination.

05/29/15 - 12:13 PM EDT

Puma Bio Restricting Access to Breast Cancer Event at ASCO Chicago

Puma Bio Restricting Access to Breast Cancer Event at ASCO Chicago

  • Tickers in this article:
  • PBYI

Puma Bio, embroiled in controversy over its breast cancer drug neratinib, is turning away some people from a company event during the American Society of Clinical Oncology (ASCO) annual meeting.

05/28/15 - 10:18 AM EDT

May 28 Premarket Briefing: 10 Things You Should Know

May 28 Premarket Briefing: 10 Things You Should Know

U.S. stock futures are sinking slightly as investors ready for unemployment numbers and pending home sales data. Chipmaker Avago Technologies is buying Broadcom for $37 billion.

05/28/15 - 08:34 AM EDT

MKM Partners' 4 Health Care Stocks to Sell Before June

MKM Partners' 4 Health Care Stocks to Sell Before June

June has historically been one of the weakest months for equities, which means stock selection -- both buying and selling -- will be critical over the short term.

05/27/15 - 09:10 AM EDT

May 27 Premarket Briefing: 10 Things You Should Know

May 27 Premarket Briefing: 10 Things You Should Know

U.S. stock futures are tentatively rising as investors digest a big cable-TV deal and debate when the Federal Reserve will raise interest rates.

05/27/15 - 07:41 AM EDT

Amazon, Apple and Chipotle Too Pricey for Your Portfolio? There's an ETF for That

Amazon, Apple and Chipotle Too Pricey for Your Portfolio? There's an ETF for That

Buying stocks whose share prices are in the hundreds or thousands of dollars can be tough for retail investors without big bankrolls. But several ETFs exist that solve that problem.

05/26/15 - 03:58 PM EDT

3 Biotech Stocks Under $10 to Trade for Breakouts

3 Biotech Stocks Under $10 to Trade for Breakouts

These under-$10 biotech stocks are within range of triggering breakout trades.

05/26/15 - 02:07 PM EDT

Energy Earnings Likely to Remain Weak in Q2, After Drop in Q1

Energy Earnings Likely to Remain Weak in Q2, After Drop in Q1

With the first-quarter earnings season behind us, data from Thomson Reuters shows earnings grew at an anemic 2.3%, the lowest level in the last four quarters.

05/26/15 - 12:34 PM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs